A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate Efficacy and Safety of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 25 Dec 2025
At a glance
- Drugs 9MW 1911 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
Most Recent Events
- 25 Dec 2025 New trial record
- 24 Dec 2025 According to Mabwell media release, the company announced that it has achieved its first patient dosing in July 2025, with an interim analysis planned after data from at least 120 patients are collected.
- 24 Dec 2025 According to Mabwell media release, the company announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).